ORM-5029 provides a HER2-targeted degrader-antibody conjugate (DAC) for targeted protein degradation and cancer research that specifically combines HER2-directed antibody targeting with a molecular-glue payload designed to induce GSPT1 degradation in HER2-expressing tumor cells.
Key Features and Benefits
- HER2-Targeted DAC: Combines antibody-mediated HER2 targeting with intracellular targeted protein degradation.
- GSPT1 Degrader Payload: Delivers a molecular-glue payload specifically designed to promote GSPT1 degradation through the ubiquitin-proteasome pathway.
- HER2 Targeting: Supports selective targeting and internalization in HER2-expressing cancer research models.
- Targeted Protein Degradation: Enables investigation of intracellular protein degradation following antibody-mediated payload delivery.
- Cleavable Linker: Supports intracellular release of the degrader payload following cellular uptake.
- HER2-Expressing Tumor Research: Supports studies specifically involving HER2-positive and HER2-low cancer models.
- Novel DAC Platform: Provides a research approach combining antibody targeting with targeted protein degradation.
Applications
- HER2-Positive Cancer Research: Supports investigation of targeted protein degradation in HER2-expressing tumor models.
- Breast Cancer Research: Useful for studying HER2-positive and HER2-low breast cancer models.
- Targeted Protein Degradation: Supports investigation of antibody-directed delivery of molecular-glue degraders.
- GSPT1 Research: Useful for studying GSPT1 degradation and associated cellular responses.
- DAC Research: Supports studies of degrader-antibody conjugate targeting, internalization, payload release, and activity.
- Cell-Based Cancer Assays: Useful for evaluating HER2-dependent uptake, GSPT1 degradation, and downstream cellular responses.
- Mechanism-of-Action Studies: Supports investigation of HER2 targeting combined with intracellular GSPT1 degradation.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody conjugates and biologically active research materials. Maintain conditions that preserve antibody and conjugate stability.
ORM-5029 combines HER2-directed targeting with GSPT1 protein degradation and specifically supports HER2-positive cancer, breast cancer, targeted protein degradation, DAC, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
